FDA Approves Label Update for Kite's Yescarta® for Relapsed/Refractory Primary Central Nervous System LymphomaBusiness Wire • 02/06/26
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 02/05/26
Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to DeclineZacks Investment Research • 02/03/26
Gilead Sciences (GILD) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 01/31/26
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026Business Wire • 01/27/26
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast CancerBusiness Wire • 01/21/26
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research • 01/13/26
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug CandidateBusiness Wire • 01/06/26
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 01/06/26